Co-authors are Jane Khoury

Co-authors are Jane Khoury, Charles J.; Kathleen Alwell, RN, Daniel Woo, MD, Matthew L read more . Flaherty, MD, Pooja Khatri, MD; Opeolu Adeoye, MD, Simona Ferioli, MD, Joseph P. Broderick, and Brett M. Kissela, MD Individual author information are on the manuscript.

11.6 % In Acceptance in Blood Clot Related Strokes Discovered - The incidence of blood clots associated with strokes fell among whites in the Greater Cincinnati / Northern Kentucky area for the first time after long-term observation study representative of strokes in Black and White reported nationwide in Strokestown: Journal of the American Heart Association. There was, however, no decrease in stroke rates among blacks - .

HST Global encourage by to FDA approval of Dendreon ProvengeHST Global, : Provenge medicament is for on promoted today by Messaging by of FDA approval for Dendreon Corps . Provenge be aimed at certain men with metastatic prostate and using man immune system functions to fight the disease. Mitchell Gold, CEO and President of Dendreon, said: 'The U.S. FDA approval of Provenge is a proof of the courage of the patient and researchers who part in our study and be the culmination of nearly 15 years of research and development by our committed employees. ' - Ron Howell, President and CEO commented: 'We congratulate Dendreon Corp. On the receipt of the clearance by the FDA, as this is a testament to the perseverance and dedication of its entire corporate team We by the FDA action in approving Provenge is desired. HST has for the purchase and development of on health care and wellness centers offer popular alternative and immunotherapy drug candidates, various cancers. The high activity undertakes in treating various cancers. '.